BioLineRx (BLRX) News Today → FW: 234x Gain (From Weiss Ratings) (Ad) Free BLRX Stock Alerts $0.68 +0.02 (+3.03%) (As of 05/3/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineBuy Rating on Bioline RX Ltd for Breakthrough Stem Cell Mobilization and Enhanced Apheresis Efficiencymarkets.businessinsider.com - April 18 at 10:09 AMBioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meetingfinance.yahoo.com - April 17 at 8:53 AMBioLineRx (NASDAQ:BLRX) Rating Increased to Sell at StockNews.commarketbeat.com - April 12 at 11:18 PMBioLineRx secures $20 million in BlackRock financinginvesting.com - April 11 at 10:42 PMBioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreementfinance.yahoo.com - April 10 at 9:47 AMBioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreementprnewswire.com - April 10 at 7:00 AMBioLineRx Announces $6 Million Registered Direct Offeringprnewswire.com - April 1 at 9:00 AMFY2024 Earnings Forecast for BioLineRx Ltd. (NASDAQ:BLRX) Issued By HC Wainwrightmarketbeat.com - March 29 at 8:38 AMShort Interest in BioLineRx Ltd. (NASDAQ:BLRX) Expands By 76.6%marketbeat.com - March 28 at 4:32 PMBioLineRx Ltd.: BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updatesfinanznachrichten.de - March 28 at 2:26 PMResearch Analysts Issue Forecasts for BioLineRx Ltd.'s Q1 2024 Earnings (NASDAQ:BLRX)marketbeat.com - March 28 at 8:22 AMBioLineRx (NASDAQ:BLRX) Upgraded to Sell at StockNews.commarketbeat.com - March 27 at 11:16 PMBioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 27 at 12:31 PMBLRX: First Aphexda Sales Recognizedfinance.yahoo.com - March 27 at 12:31 PMBioLineRx (NASDAQ:BLRX) Announces Earnings Resultsmarketbeat.com - March 27 at 9:30 AMBuy Rating Affirmed for BioLineRx: Strong Financials and Expanding Market Presence Fuel Analyst Optimismmarkets.businessinsider.com - March 27 at 12:47 AMBioLineRx's (BLRX) "Buy" Rating Reiterated at HC Wainwrightmarketbeat.com - March 26 at 12:44 PMBioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updatesprnewswire.com - March 26 at 7:00 AMBioLineRx (BLRX) to Release Quarterly Earnings on Tuesdaymarketbeat.com - March 21 at 11:26 AMBioLineRx to Report 2023 Annual Financial Results on March 26, 2024prnewswire.com - March 20 at 7:00 AMBioLineRx Ltd. (NASDAQ:BLRX) Sees Large Decrease in Short Interestmarketbeat.com - March 19 at 8:39 AMBioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Productionfinance.yahoo.com - March 4 at 7:38 AMBioLineRx begins phase 2 trial for pancreatic cancer treatmentinvesting.com - March 1 at 10:23 AMBLRX Mar 2024 1.000 callfinance.yahoo.com - March 1 at 10:23 AMBioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)prnewswire.com - February 28 at 7:00 AMBLRX: Poster Presentationsfinance.yahoo.com - February 26 at 2:18 PM3 Top Penny Stocks for 5,000% Upside in 2024 and Beyondinvestorplace.com - February 25 at 2:12 PMBLRX May 2024 1.000 putca.finance.yahoo.com - February 23 at 2:16 PMBioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®finance.yahoo.com - February 16 at 7:15 AMBioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®prnewswire.com - February 16 at 7:00 AMBioLineRx Ltd. (NASDAQ:BLRX) Sees Significant Drop in Short Interestmarketbeat.com - December 29 at 12:17 PMBioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Diseasefinance.yahoo.com - December 21 at 10:12 AMBioLineRx: Still A Buy, With Some Questionsseekingalpha.com - December 4 at 11:58 PMBioLineRx: Weighing Aphexda's Breakthrough Against Financial Challengesseekingalpha.com - December 3 at 10:01 AMBioLineRx Ltd. (NASDAQ:BLRX) Q3 2023 Earnings Call Transcriptinsidermonkey.com - November 21 at 5:06 PMBioline RX Receives Buy Rating Despite Lower Than Expected Q3 Results: Expansions, Partnerships, and Promising Clinical Trials Signal Future Growthmarkets.businessinsider.com - November 21 at 10:12 AMBLRX: A Series of Fortunate Eventsfinance.yahoo.com - November 21 at 10:12 AMBioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updatesfinance.yahoo.com - November 20 at 8:10 AMbiolinerx Q3 2023 Earnings Previewmsn.com - November 17 at 2:28 PMBioLineRx to Report Third Quarter 2023 Results on November 20, 2023finance.yahoo.com - November 13 at 7:32 AMWeek In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7Bmsn.com - November 5 at 8:08 AMBioLineRx Shares Rise 12% After Licensing Agreement for Motixafortidemarketwatch.com - November 2 at 7:25 PMMSQ Ventures: BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Venturesfinanznachrichten.de - October 31 at 9:28 AMBioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Venturesfinance.yahoo.com - October 31 at 9:28 AMBioLineRx Concludes License Deal With Guangzhou Gloria To Develop Motixafortide In Asiamarkets.businessinsider.com - October 12 at 9:18 AMBioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investmentfinance.yahoo.com - October 12 at 9:18 AMBioLineRx (BLRX) Stock Down on Negative Heart Disease Treatment Resultsthestreet.com - October 9 at 7:08 PMBioLineRx Touts Encouraging Data From Therapy Trial For First Line Pancreatic Cancermsn.com - September 28 at 2:21 PMBioLineRx Ltd. (NASDAQ:BLRX) Short Interest Up 86.3% in Septembermarketbeat.com - September 28 at 7:22 AMBioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic Cancerfinance.yahoo.com - September 19 at 9:02 AM Get BioLineRx News Delivered to You Automatically Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Automatic Income (from home) (Ad)For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year. Just click here now to watch my presentation for free. BLRX Media Mentions By Week BLRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BLRX News Sentiment▼0.000.43▲Average Medical News Sentiment BLRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BLRX Articles This Week▼01▲BLRX Articles Average Week Get BioLineRx News Delivered to You Automatically Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CKPT News Today CALC News Today ELDN News Today IMRX News Today FIXX News Today GANX News Today JAGX News Today RPHM News Today AADI News Today RMTI News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BLRX) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchStock-Picking AI Predicts #1 Stock of 2024AltimetryHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceThe asset beating inflation by 4xColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLineRx Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.